Is It Smart To Buy Amoy Diagnostics Co., Ltd. (SZSE:300685) Before It Goes Ex-Dividend?
Is It Smart To Buy Amoy Diagnostics Co., Ltd. (SZSE:300685) Before It Goes Ex-Dividend?
Amoy Diagnostics Co., Ltd. (SZSE:300685) stock is about to trade ex-dividend in 2 days. The ex-dividend date is usually set to be one business day before the record date which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. Thus, you can purchase Amoy Diagnostics' shares before the 30th of May in order to receive the dividend, which the company will pay on the 30th of May.
艾德生物股票將於2天后除息。除息日通常設置爲股權登記日前一天,即您必須作爲股東出現在公司賬簿上,才能在分紅日收到分紅。除息日是需要注意的重要日期,因爲在此日期之後或之前購買股票的結算可能會遲到,導致不能在股權登記日顯示。因此,您可以在5月30日之前購買艾德生物的股票,以獲取30日支付的分紅。
The company's next dividend payment will be CN¥0.15 per share. Last year, in total, the company distributed CN¥0.15 to shareholders. Last year's total dividend payments show that Amoy Diagnostics has a trailing yield of 0.8% on the current share price of CN¥18.43. If you buy this business for its dividend, you should have an idea of whether Amoy Diagnostics's dividend is reliable and sustainable. That's why we should always check whether the dividend payments appear sustainable, and if the company is growing.
該公司的下一個分紅將爲每股人民幣0.15元。去年,該公司向股東派發了人民幣0.15元的總分紅。去年的總分紅額表明,艾德生物股票目前的收益率爲0.8%。如果您購買該股票是爲了分紅,您應該了解艾德生物的分紅是否可靠和可持續。這就是爲什麼我們應該始終檢查分紅支付是否可持續,以及公司的增長情況。
If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Amoy Diagnostics paid out just 22% of its profit last year, which we think is conservatively low and leaves plenty of margin for unexpected circumstances. A useful secondary check can be to evaluate whether Amoy Diagnostics generated enough free cash flow to afford its dividend. Luckily it paid out just 20% of its free cash flow last year.
如果公司支付的股息大於其盈利,則可能導致股息無法維持,這很不理想。去年,艾德生物僅支付了22%的利潤,我們認爲這是保守的水平,留有足夠的餘地用於意外情況。有用的輔助檢查是評估艾德生物是否產生足夠的自由現金流來支付其股息。幸運的是,去年它只支付了其自由現金流的20%。
It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.
看到股息既有盈利也有現金流的覆蓋是令人鼓舞的。這通常表明股息是可持續的,只要收益沒有急劇下降。
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
點擊此處查看公司的支付比率以及未來分紅的分析師預期。
![historic-dividend](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240528/0-413b39c29586d037df47b51231ebabd0-0-18b72e115e4164dd972a2f139fea73b2.png/big)
Have Earnings And Dividends Been Growing?
收益和股息一直在增長嗎?
Stocks in companies that generate sustainable earnings growth often make the best dividend prospects, as it is easier to lift the dividend when earnings are rising. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. For this reason, we're glad to see Amoy Diagnostics's earnings per share have risen 16% per annum over the last five years. The company has managed to grow earnings at a rapid rate, while reinvesting most of the profits within the business. Fast-growing businesses that are reinvesting heavily are enticing from a dividend perspective, especially since they can often increase the payout ratio later.
以產生可持續的盈利增長的公司的股票通常是最好的分紅前景,因爲在盈利增長時,提高分紅比率更容易。如果收益下降並且公司被迫削減股息,則投資者可能會看到其投資價值蕩然無存。因此,我們很高興地看到艾德生物每股收益在過去五年中年平均增長了16%。該公司成功地以快速的速度增長了收益,並將大部分利潤重新投資於業務中。從股息的角度來看,這些積極的增長業務尤其具有吸引力,特別是因爲它們通常可以在以後增加支付比率。
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Since the start of our data, six years ago, Amoy Diagnostics has lifted its dividend by approximately 20% a year on average. Both per-share earnings and dividends have both been growing rapidly in recent times, which is great to see.
衡量公司分紅前景的另一個關鍵方法是衡量其歷史分紅增長率。自我們的數據開始以來,即六年前,艾德生物每年平均提高約20%的股息。近段時間,每股收益和股息都在快速增長,這是非常好的跡象。
To Sum It Up
總結一下
Is Amoy Diagnostics worth buying for its dividend? Amoy Diagnostics has been growing earnings at a rapid rate, and has a conservatively low payout ratio, implying that it is reinvesting heavily in its business; a sterling combination. It's a promising combination that should mark this company worthy of closer attention.
對於它的分紅,艾德生物值得購買嗎?艾德生物的每股收益以快速的速度增長,並且分紅比率保守且較低,這意味着它正在積極地將資金投入其業務中;這是一個卓越的組合。這是一個值得更加關注的有前途的公司。
In light of that, while Amoy Diagnostics has an appealing dividend, it's worth knowing the risks involved with this stock. For example - Amoy Diagnostics has 1 warning sign we think you should be aware of.
因此,儘管艾德生物具有吸引力的股息,但了解該股票的風險也很重要。例如,請注意-艾德生物有1個警告標誌,我們認爲您應該了解。
If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.
如果你在尋找強勁的股息支付者,我們建議查看我們的頂級股息股票選擇。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。